Pfizer has announced a revision of its profit forecast for 2025, now expecting an adjusted profit between $3 and $3.15 per share, compared to the previous estimate of $2.90–$3.10, due to solid performance and cost reductions. Quarterly revenues were $16.65 billion, slightly above estimates, but 6% lower than the previous year, influenced by decreased demand for the Comirnaty vaccine and the Paxlovid treatment. Net profit was $3.54 billion, impacted by a one-time tax of $1.35 billion. Pfizer maintains its total revenue estimate for 2025 between $61 and $64 billion and plans to cut costs by $7.7 billion by 2027. The company benefits from an agreement with the Trump administration to reduce drug prices in the U.S. in exchange for tariff exemptions. Pfizer is diversifying its portfolio through acquisitions in oncology and continues to develop drugs, despite declining sales of Covid products. Pfizer's shares have dropped by 7% since the beginning of the year.
Sources
Pfizer majorează prognoza de profit, în pofida scăderii vânzărilor
Pfizer a depăşit estimările privind rezultatele financiare şi a majorează prognoza de profit, în pofida scăderii vânzărilor
Pfizer își majorează prognoza de profit, după rezultate peste așteptări în trimestrul trei
Latest News
17:30
Gheorghie Vlad, the Chief of the General Staff of Defense, met with his Hungarian counterpart to discuss regional security.
17:20
The Finnish government will provide Ukraine with 28.5 million euros for the reconstruction of the energy sector affected by Russian attacks.
17:19
The Ministry of Energy announces that the National Electric Power System is stable, despite the shutdown of the reactors at Cernavodă. Romania will import up to 2,300 MW to cover the energy needs.
17:16
Romania supports Spain's efforts to recognize Catalan, Basque, and Galician as official EU languages.
17:14
Cristi Borcea's son, Patrick, would be under electronic monitoring after beating his ex-girlfriend.
See more news